Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders

Abstract

Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders using the oral cannabinoid pharmaceutical compositions are described.

What is claimed is: 
     
         1 . An oral pulse-release dosage form, comprising a total daily dose of a first cannabinoid active pharmaceutical ingredient (API 1 ) and a total daily dose of a second cannabinoid API (API 2 ), wherein the oral pulse-release dosage form comprises:
 a first pulse-release component (C 1 ) comprising a first portion (P 1 ) of the first cannabinoid API (API 1 P 1 ) and a first portion (P 1 ) of the second cannabinoid API (API 2 P 1 ); and   at least a second pulse-release component (C 2 ) comprising a second portion (P 2 ) of the first cannabinoid API (API 1 P 2 ) and a second portion (P 2 ) of the second cannabinoid API (API 2 P 2 );
 wherein the total daily dose of each of the API 1  and the API 2  is divided between the first portion (P 1 ) in the first pulse-release component (C 1 ) and at least the second portion (P 2 ) in the at least second pulse-release component (C 2 ); and 
 wherein when the pulse-release dosage form is placed in an aqueous solution of 0.1N HCl pH 1.1 for 2 hours followed by 8 hours in sodium phosphate buffer at pH6.8, at 37° C.±0.5° C., 
 the pulse-release dosage form provides release of the API 1 P 2  and the API 2 P 2  beginning from 2 to 6 hours after release of the API 1 P 1  and the API 2 P 1  begins. 
   
     
     
         2 . The oral pulse-release dosage form of  claim 1 , wherein:
 the pulse-release dosage form provides a second time of peak release rate (PRR 2 ) of each of the API 1  (PRR 2 API 1 ) and the API 2  (PRR 2 API 2 ) from about 2 to 6 hours after a first time of peak release rate (PRR 1 ).   
     
     
         3 . The oral pulse-release dosage form of  claim 2 , wherein:
 the PRR 1  is after 1-2 hours.   
     
     
         4 . The oral pulse-release dosage form of  claim 1 , wherein:
 the first cannabinoid API 1  is delta-9-tetrahydrocannabinol (THC) and the second cannabinoid API 2  is cannabinol (CBN); and   the total daily dose of the THC is from 1 mg to 40 mg and the total daily dose of the CBN is from 2.5 mg to 100 mg.   
     
     
         5 . The oral pulse-release dosage form of  claim 1 , wherein:
 the first cannabinoid API 1  is THC and the second cannabinoid API 2  is CBN; and   the total daily dose of the THC is selected from: at least 1 mg, at least 2 mg, at least 3 mg, at least 4 mg, at least 5 mg, at least 6 mg, at least 8 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, and at least 35 mg, and the total daily dose of the CBN is selected from: at least 2.5 mg, at least 3 mg, at least 4 mg, at least 5 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, and at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, and at least 95 mg.   
     
     
         6 . The oral pulse-release dosage form of  claim 1 , wherein:
 the first pulse-release component (C 1 ) is an immediate release (IR) formulation of the first cannabinoid API 1  and the second cannabinoid API 2 , comprising:
 the first portion (P 1 ) of the first cannabinoid API (API 1 P 1 ) and a first portion (P 1 ) of the second cannabinoid API (API 2 P 1 ); 
 one or more binders; 
 one or more disintegrants; 
 one or more lubricants; and 
 one or more flow aids; and 
   the second pulse-release component (C 2 ) is a delayed release (DR) formulation of the first cannabinoid API 1  and the second cannabinoid API 2 , comprising:
 the second portion (P 2 ) of the first cannabinoid API (API 1 P 2 ) and a second portion (P 2 ) of the second cannabinoid API (API 2 P 2 ); 
 one or more binders; 
 one or more lubricants; and 
 one or more flow aids; 
 wherein the second pulse-release component is coated with a delayed-release layer comprising one or more pH-dependent and/or non-pH-dependent polymers, and optionally one or more plasticizers, one or more pore formers, and/or one or lubricants. 
   
     
     
         7 . The oral pulse-release dosage form of  claim 1 , wherein:
 for each API, the first portion (P 1 ) is independently selected from 25% to 75% of the total daily dose, and for each API the second portion (P 2 ) is independently selected from 25% to 75% of the total daily dose.   
     
     
         8 . The oral pulse-release dosage form of  claim 6 , wherein, in the first pulse-release component (C 1 ), the second pulse-release component (C 2 ), or both, when present:
 the binders comprise from 1 to 60% (w/w);   the disintegrants comprise from 0.05 to 15% (w/w);   the lubricants comprise from 0.5 to 5% (w/w);   the flow aids comprise from 0.05 to 0.5% (w/w);   and   the pH-dependent and/or non-pH-dependent polymers comprise from 0.5 to 35% (w/w).   
     
     
         9 . The oral pulse-release dosage form of  claim 1 , wherein:
 the first pulse-release component (C 1 ) comprises:
 from 0.5 mg to 30 mg of the first cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is THC; 
 from 1.25 mg to 75 mg of the second cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is CBN; and 
 microcrystalline cellulose, hydroxypropylmethylcellulose, and magnesium stearate; and 
   the second pulse-release component (C 2 ) comprises:
 from 0.5 mg to 30 mg of the first cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is THC; 
 from 1.25 mg to 75 mg of the second cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is CBN; and 
 microcrystalline cellulose, methacrylic acid copolymer, magnesium stearate, and colloidal silicone dioxide. 
   
     
     
         10 . An oral pulse-release dosage form, comprising a total daily dose of a first cannabinoid active pharmaceutical ingredient (API 1 ) and a total daily dose of a second cannabinoid API (API 2 ), wherein the pulse-release dosage form comprises:
 a first pulse-release component (C 1 ) comprising a first portion (P 1 ) of the first cannabinoid API (API 1 P 1 ) and a first portion (P 1 ) of the second cannabinoid API (API 2 P 1 );   a second pulse-release component (C 2 ) comprising a second portion (P 2 ) of the first cannabinoid API (API 1 P 2 ) and a second portion (P 2 ) of the second cannabinoid API (API 2 P 2 ); and   at least a third pulse-release component (C 3 ) comprising a third portion (P 3 ) of the first cannabinoid API (API 1 P 3 ) and a third portion (P 3 ) of the second cannabinoid API (API 2 P 2 );
 wherein the total daily dose of each of the API 1  and the API 2  is divided between the first portion (P 1 ) in the first pulse-release component (C 1 ), the second portion (P 2 ) in the second pulse-release component (C 2 ), and at least the third portion (P 3 ) in the at least third pulse-release component (C 3 ); and 
 wherein when the pulse-release dosage form is placed in an aqueous solution of 0.1N HCl pH 1.1 for 2 hours followed by 8 hours in sodium phosphate buffer at pH6.8, at 37° C.±0.5° C., 
 the pulse-release dosage form provides release of the API 1 P 2  and the API 2 P 2  beginning from 1 to 4 hours after release of the API 1 P 1  and the API 2 P 1  begins, and release of the API 1 P 3  and the API 2 P 3  beginning from 1 to 4 hours after release of the API 1 P 2  and the API 2 P 2  begins. 
   
     
     
         11 . The oral pulse-release dosage form of  claim 10 , wherein:
 the pulse-release dosage form provides a second time of peak release rate (PRR 2 ) of each of the API 1  (PRR 2 API 1 ) and the API 2  (PRR 2 API 2 ) from about 1 to 4 hours after a first PRR (PRR 1 ) and a third time of peak release rate (PRR 3 ) of each of the API 1  (PRR 3 API 1 ) and the API 2  (PRR 3 API 2 ) from about 1 to 4 hours after the second time of PRR (PRR 2 ).   
     
     
         12 . The oral pulse-release dosage form of  claim 11 , wherein:
 the PRR 1  is after 1-2 hours.   
     
     
         13 . The oral pulse-release dosage form of  claim 10 , wherein:
 the first cannabinoid API 1  is delta-9-tetrahydrocannabinol (THC) and the second cannabinoid API 2  is cannabinol (CBN); and   the total daily dose of the THC is from 10 mg to 40 mg and the total daily dose of the CBN is from 5 mg to 100 mg.   
     
     
         14 . The oral pulse-release dosage form of  claim 10 , wherein:
 the first cannabinoid API 1  is THC and the second cannabinoid API 2  is CBN; and   the total daily dose of the THC is selected from: at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, and at least 35 mg, and the total daily dose of the CBN is selected from: at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, and at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, and at least 95 mg.   
     
     
         15 . The oral pulse-release dosage form of  claim 10 , wherein:
 the first pulse-release component (C 1 ) is an immediate release (IR) formulation of the first cannabinoid API 1  and the second cannabinoid API 2 , comprising:
 the first portion (P 1 ) of the first cannabinoid API (API 1 P 1 ) and a first portion (P 1 ) of the second cannabinoid API (API 2 P 1 ); 
 one or more binders; 
 one or more disintegrants; 
 one or more lubricants; and 
 one or more flow aids; and 
   the second pulse-release component (C 2 ) is a delayed release (DR) formulation of the first cannabinoid API 1  and the second cannabinoid API 2 , comprising:
 the second portion (P 2 ) of the first cannabinoid API (API 1 P 2 ) and a second portion (P 2 ) of the second cannabinoid API (API 2 P 2 ); 
 one or more binders; 
 one or more lubricants; 
 one or more flow aids; and 
   wherein the second pulse-release component is coated with a first delayed-release layer comprising one or more pH-dependent and/or non-pH-dependent polymers, and optionally one or more plasticizers, one or more pore formers, and/or one or lubricants; and   the third pulse-release component (C 3 ) is a delayed release (DR) formulation of the first cannabinoid API 1  and the second cannabinoid API 2 , comprising:
 the third portion (P 3 ) of the first cannabinoid API (API 1 P 3 ) and a third portion (P 3 ) of the second cannabinoid API (API 2 P 3 ); 
 one or more binders; 
 one or more lubricants; and 
 one or more flow aids; and 
 wherein the third pulse-release component is coated with a second delayed-release layer comprising one or more pH-dependent and/or non-pH-dependent polymers, and optionally one or more plasticizers, one or more pore formers, and/or one or lubricants. 
   
     
     
         16 . The oral pulse-release dosage form of  claim 10 , wherein:
 for each API, the first portion (P 1 ) is independently selected from 25% to 75% of the total daily dose, for each API, the second portion (P 2 ) is independently selected from 25% to 75% of the total daily dose, and, for each API, the third portion (P 3 ) is independently selected from 25% to 75% of the total daily dose.   
     
     
         17 . The oral pulse-release dosage form of  claim 15 , wherein, in the first pulse-release component (C 1 ), the second pulse-release component (C 2 ), and/or the third pulse-release component (C 3 ), when present:
 the binders comprise from 1 to 60% (w/w);   the disintegrants comprise from 0.05 to 15% (w/w);   the lubricants comprise from 0.5 to 5% (w/w);   the flow aids comprise from 0.05 to 0.5% (w/w);   and   the pH-dependent and/or non-pH-dependent polymers comprise from 0.5 to 35% (w/w).   
     
     
         18 . The oral pulse-release dosage form of  claim 10 , wherein:
 the first pulse-release component (C 1 ) comprises:
 from 2.5 mg to 30 mg of the first cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is THC; 
 from 1.25 mg to 75 mg of the second cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is CBN; and 
 microcrystalline cellulose, hydroxypropylmethylcellulose, croscormellose sodium, and magnesium stearate; 
   the second pulse-release component (C 2 ) comprises:
 from 2.5 mg to 30 mg of the first cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is THC; 
 from 1.25 mg to 75 mg of the second cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is CBN; and 
   microcrystalline cellulose, cellulose acetate phthalate, and magnesium stearate; and   the third pulse-release component (C 3 ) comprises:
 from 2.5 mg to 30 mg of the first cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is THC; 
 from 1.25 mg to 75 mg of the second cannabinoid active pharmaceutical ingredient (API 1 ), wherein the API 1  is CBN; and 
   microcrystalline cellulose, methacrylic acid copolymer, and magnesium stearate.   
     
     
         19 - 32 . (canceled)